Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors

<table class="table-group" id="tab3"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td class="align_left">Level</td><td class="align_center">Description</td><td class="align_center">NCCN guideline</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td class="align_left">G1</td><td class="align_center">Mild pain and/or stiffness, no limitation of ADL</td><td class="align_center">Continue immunotherapy; prednisone, the initial dose of 5-20 mg/D ×6 weeks, then decreased in 4-6 weeks.</td></tr><tr><td class="align_left">G2</td><td class="align_center">Moderate pain and/or stiffness, affecting instrumental ADL</td><td class="align_center" rowspan="2">Stop immunotherapy; prednisone 10-20 mg/D, decreased in 8-12 weeks; if there is no improvement, please consult with the rheumatology department.</td></tr><tr><td class="align_left">G3</td><td class="align_center">Severe pain and/or stiffness, affecting self-care ADL</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Management of immunotherapy-related polymyalgia rheumatica.</div>

Journal of Immunology Research

tab3

Table 3

Table 3: Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors 